MX378707B - Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. - Google Patents

Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.

Info

Publication number
MX378707B
MX378707B MX2016014634A MX2016014634A MX378707B MX 378707 B MX378707 B MX 378707B MX 2016014634 A MX2016014634 A MX 2016014634A MX 2016014634 A MX2016014634 A MX 2016014634A MX 378707 B MX378707 B MX 378707B
Authority
MX
Mexico
Prior art keywords
relates
disorders
treatment
compounds
inhibitor compounds
Prior art date
Application number
MX2016014634A
Other languages
English (en)
Other versions
MX2016014634A (es
Inventor
Franz Obermayr
Stefan Sperl
Original Assignee
Panoptes Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptes Pharma Ges M B H filed Critical Panoptes Pharma Ges M B H
Publication of MX2016014634A publication Critical patent/MX2016014634A/es
Publication of MX378707B publication Critical patent/MX378707B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere en general al campo de productos terapéuticos oculares y el desarrollo de los mismos para uso en humanos o en animales. Más particularmente, se refiere a compuestos inhibidores de DHODH y su uso para el tratamiento de enfermedades y de trastornos oftálmicos. La invención también se refiere a la administración local de dichas composiciones oftálmicas, y en particular para su administración intravítrea. La invención también se refiere a formulaciones de liberación controlada de agentes terapéuticamente activos, en particular de compuestos inhibidores de DHODH administrados por vía intraocular, en particular en el segmento posterior del ojo.
MX2016014634A 2014-05-08 2015-05-08 Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. MX378707B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167490 2014-05-08
EP14170616 2014-05-30
PCT/EP2015/060166 WO2015169944A1 (en) 2014-05-08 2015-05-08 Compounds for treating ophthalmic diseases and disorders

Publications (2)

Publication Number Publication Date
MX2016014634A MX2016014634A (es) 2017-04-10
MX378707B true MX378707B (es) 2025-03-10

Family

ID=53051826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014634A MX378707B (es) 2014-05-08 2015-05-08 Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.

Country Status (18)

Country Link
US (3) US11730716B2 (es)
EP (1) EP3139914B1 (es)
JP (1) JP6629840B2 (es)
KR (1) KR102312186B1 (es)
CN (2) CN116077665A (es)
AU (1) AU2015257651B2 (es)
BR (1) BR112016025997A8 (es)
CA (1) CA2947067C (es)
CL (1) CL2016002812A1 (es)
ES (1) ES2960598T3 (es)
HK (1) HK1231417A1 (es)
IL (1) IL248732B (es)
MX (1) MX378707B (es)
NZ (1) NZ725574A (es)
PL (1) PL3139914T3 (es)
SG (1) SG11201608835VA (es)
WO (1) WO2015169944A1 (es)
ZA (1) ZA201607260B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
HK1231417A1 (zh) * 2014-05-08 2017-12-22 帕诺泰斯制药有限公司 用於治疗眼科疾病和障碍的化合物
PL3193901T3 (pl) 2014-12-23 2018-10-31 4D Pharma Research Limited Polipeptyd pyrynowy i immunomodulacja
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
MD3206700T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017085520A1 (en) 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6961879B2 (ja) * 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JP6441536B2 (ja) 2016-03-04 2018-12-19 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ 細菌株を含む組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CN110662539B (zh) 2017-04-24 2023-08-15 奥里吉恩探索技术有限公司 三取代的苯并三唑衍生物作为二氢乳清酸加氧酶抑制剂的使用方法
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
MA49010B1 (fr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
LT3600363T (lt) 2017-06-14 2021-02-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
EP3639855A4 (en) * 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3755324B1 (en) 2018-02-20 2025-07-30 Les Laboratoires Servier Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
IL276918B2 (en) 2018-03-09 2024-10-01 Panoptes Pharma Ges M B H Ophthalmic formulation comprising albumin and an active compound
JP7358373B2 (ja) * 2018-03-16 2023-10-10 イミュニック アクチェンゲゼルシャフト 抗炎症薬、免疫調節薬及び抗増殖薬としての新規カルシウム塩多形
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US20210308117A1 (en) 2020-03-20 2021-10-07 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN116322773A (zh) * 2020-04-21 2023-06-23 马萨诸塞大学 用于治疗年龄相关性黄斑变性的方法和组合物
CN111638341A (zh) * 2020-07-01 2020-09-08 山东凯歌智能机器有限公司 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法
EP4228640A1 (en) * 2020-10-15 2023-08-23 ASLAN Pharmaceuticals Pte Ltd Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CA3215002A1 (en) 2021-04-09 2022-10-13 Christian Gege Deuterated dhodh inhibitors
UY40087A (es) * 2021-12-23 2023-06-30 Immunic Ag Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico.
IL315335A (en) * 2022-03-01 2024-10-01 Kiora Pharmaceuticals Gmbh salts of dehydrogenase inhibitor (DHOD)
WO2023172818A1 (en) * 2022-03-09 2023-09-14 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor
EP4637715A1 (en) * 2022-12-22 2025-10-29 Cavalry Biosciences, Inc. Compositions and methods for treating meibomain gland dysfunction
PY2454653A (es) 2023-06-28 2025-04-21 Immunic Ag Inhibidores de dhodh heteroaromáticos

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103836A (ja) 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
JP3058920B2 (ja) 1996-04-19 2000-07-04 一男 坪田 アルブミンを有効成分とする医薬組成物
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
US20040221855A1 (en) * 2002-10-17 2004-11-11 Paul Ashton Methods for monitoring treatment of disease
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
PL209303B1 (pl) 2002-12-23 2011-08-31 4Sc Ag Związek aromatyczny, kompozycja farmaceutyczna zawierająca związek aromatyczny i zastosowanie związku aromatycznego jako środka przeciwzapalnego, immunomodulującego i antyproliferacyjnego
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) * 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
RU2387652C2 (ru) 2004-03-11 2010-04-27 Актелион Фармасьютиклз Лтд Производные тетрагидропиридоиндола
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
US20070082841A1 (en) 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2009270356A (ja) 2008-05-08 2009-11-19 Yoshinobu Hayashi アスベスト含有被覆層剥ぎ取り物の処理方法
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2717914B1 (en) * 2011-06-10 2019-10-30 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
MX2016013341A (es) 2014-04-11 2017-09-01 Panoptes Pharma Gmbh Agentes antiinflamatorios como compuestos virostaticos.
HK1231417A1 (zh) * 2014-05-08 2017-12-22 帕诺泰斯制药有限公司 用於治疗眼科疾病和障碍的化合物
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
IL276918B2 (en) 2018-03-09 2024-10-01 Panoptes Pharma Ges M B H Ophthalmic formulation comprising albumin and an active compound
CA3215002A1 (en) 2021-04-09 2022-10-13 Christian Gege Deuterated dhodh inhibitors
IL315335A (en) 2022-03-01 2024-10-01 Kiora Pharmaceuticals Gmbh salts of dehydrogenase inhibitor (DHOD)
WO2023172818A1 (en) 2022-03-09 2023-09-14 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor

Also Published As

Publication number Publication date
IL248732B (en) 2019-07-31
AU2015257651B2 (en) 2020-01-23
CA2947067C (en) 2023-02-14
US20170071904A1 (en) 2017-03-16
EP3139914C0 (en) 2023-07-26
EP3139914B1 (en) 2023-07-26
US20230285355A1 (en) 2023-09-14
US12364680B2 (en) 2025-07-22
SG11201608835VA (en) 2016-11-29
BR112016025997A2 (pt) 2017-08-15
MX2016014634A (es) 2017-04-10
NZ725574A (en) 2022-08-26
US20250381167A1 (en) 2025-12-18
HK1231417A1 (zh) 2017-12-22
AU2015257651A1 (en) 2016-11-10
JP2017514917A (ja) 2017-06-08
IL248732A0 (en) 2017-01-31
BR112016025997A8 (pt) 2021-07-06
US11730716B2 (en) 2023-08-22
CN116077665A (zh) 2023-05-09
KR102312186B1 (ko) 2021-10-14
JP6629840B2 (ja) 2020-01-15
CN106572968A (zh) 2017-04-19
ES2960598T3 (es) 2024-03-05
WO2015169944A1 (en) 2015-11-12
EP3139914A1 (en) 2017-03-15
PL3139914T3 (pl) 2023-11-27
ZA201607260B (en) 2018-05-30
CA2947067A1 (en) 2015-11-12
CL2016002812A1 (es) 2017-03-17
KR20160147023A (ko) 2016-12-21

Similar Documents

Publication Publication Date Title
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
SA518391624B1 (ar) Ror- منظمات جاما
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MX393057B (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
MX362485B (es) Nuevos inhibidores de rock.
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
MY201535A (en) Therapeutic compounds
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX381932B (es) Composicion intranasal que comprende betahistina.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
BR112017021374A2 (pt) ácido pirrolidona carboxílico (pca) para uso oftálmico
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient